AUS
NZ
UK
CA
USA
IND
Highlights:
- Enrollment for Phase 3 DIAMOND-1 and DIAMOND-2 trials has surged, with 70% and 40% of patients enrolled, respectively.
- The DIAMOND program has expanded its committees with globally recognized retina specialists.
- OCS-01 could redefine DME treatment as the first topical eye drop therapy.
Oculis Holding AG, a biopharmaceutical company focused on advancing eye care, has announced significant progress in its Phase 3 DIAMOND trials for OCS-01 eye drops, aimed at treating diabetic macular edema (DME). The momentum in patient enrollment has accelerated notably since the end of Q2 2024, with approximately 70% of participants enrolled in the DIAMOND-1 trial and about 40% in the DIAMOND-2 trial as of early October 2024.
The DIAMOND program consists of two pivotal Phase 3, double-masked, randomized, multi-center trials designed to evaluate the efficacy and safety of OCS-01 in DME patients. This condition is a leading cause of vision loss among diabetic patients, affecting millions globally. Given the current treatment landscape, which largely relies on injections or laser therapies, OCS-01’s development as a topical eye drop could represent a transformative approach to managing this debilitating condition.
Dr. Arshad M. Khanani, the Chairperson of the DIAMOND Program Steering Committee, expressed enthusiasm about the trial's progress. He noted, “I am honored to chair the DIAMOND steering committee, comprised of leading experts from around the globe, as we support the outstanding team at Oculis in the late-stage development of OCS-01. The results from Stage 1 of the DIAMOND Phase 3 program are promising, showing that patients treated with OCS-01 experienced significant improvements in visual acuity and a clinically meaningful reduction in macular edema.” His comments reflect the high expectations surrounding the potential impact of OCS-01 on the lives of those affected by DME.
The recent enrollment milestones not only highlight the enthusiasm for OCS-01 but also underscore Oculis’ commitment to expediting the development of innovative therapies. Riad Sherif, CEO of Oculis, shared his satisfaction with the enrollment speed, stating, “We are very pleased with the strong momentum in patient enrollment in DIAMOND-1 and DIAMOND-2 Phase 3 trials which continues to exceed our expectations.” He also emphasized the significance of having a distinguished group of global experts on the DIAMOND program committees, which provides strategic oversight and guidance as the trials progress.
The involvement of globally renowned retina specialists in the DIAMOND program committees enhances Oculis’ capacity to navigate the complexities of late-stage development. Their expertise will be invaluable as the company seeks to bring OCS-01 to market. This treatment has the potential not just to improve patient outcomes but to revolutionize the way DME is managed, moving towards a less invasive and more patient-friendly approach.
If successful, OCS-01 could become the first non-invasive topical eye drop therapy for DME, significantly changing the treatment paradigm. This advancement would be especially welcome in a field where patient adherence to treatment can be challenging due to the invasive nature of current options.
As Oculis moves forward with the DIAMOND trials, the company remains focused on its mission to save sight and improve eye care globally. The progress made thus far is promising, and stakeholders will be closely monitoring the upcoming developments as Oculis advances its innovative approach to treating diabetic macular edema.
